Literature DB >> 617957

Condition-dependent immunoregulatory control of contact sensitivity by levamisole.

D E Griswold, D T Walz.   

Abstract

The immunostimulatory activity of levamisole [1-(-),2,3,5,6-tetrahydro-6-phenylimidazo(2,1-beta)-thiazole] was investigated using oxazolone-induced contact sensitivity in C57Bl mice. Oxazolone sensitivity was induced by applying 0.1 ml of 3 or 5% oxazolone in ethanol to the shaved abdomen (day 0). Challenge with oxazolone followed on day 2 (45 h) or day 3, and was accomplished by painting a 1--5% solution of oxazolone in ethanol to the left hind paw. The response at 24 h was determined plethysmographically. Levamisole (50 mg/kg, p.o., days 0--3 or day 0 only) failed to stimulate consistently the oxazolone response in a 3-day (minimal) sensitization period regimen. Use of a subliminal (45 h) sensitization, by contrast, revealed a consistent immunostimulatory effect of levamisole (12.5--100 mg/kg, p.o., day 0 only). It is speculated that the observed difference in levamisole effectiveness is attributable to (1) the ability of levamisole to stimulate both effector and suppressor mechanisms, and (2) the apparent absence of significant suppressor influence at 2-day postsensitization, leaving only the effector mechanism to be stimulated by levamisole.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 617957     DOI: 10.1007/bf00921007

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  24 in total

1.  Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease.

Authors:  B Ramot; M Biniaminov; C Shoham; E Rosenthal
Journal:  N Engl J Med       Date:  1976-04-08       Impact factor: 91.245

2.  Suppression of autoimmune hemolytic anemia in New Zealand (NZB) mice by syngeneic young thymocytes.

Authors:  M E Gershwin; A D Steinberg
Journal:  Clin Immunol Immunopathol       Date:  1975-05

3.  Letter: Levamisole (NSC-177023) in clinical immunotherapy.

Authors:  W K Amery
Journal:  Cancer Treat Rep       Date:  1976-03

4.  The effect of levamisole on cell-mediated immunity and suppressor cell function.

Authors:  D Sampson; A Lui
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

5.  Cancer immunotherapy: focus on the drug levamisole.

Authors:  J L Marx
Journal:  Science       Date:  1976-01-09       Impact factor: 47.728

6.  Letter: Treatment of recurrent aphthous stomatitis and herpes with levamisole.

Authors:  J Symoens; J Brugmans
Journal:  Br Med J       Date:  1974-12-07

7.  Quantification and pharmacological dissection of oxazolone-induced contact sensitivity in the mouse.

Authors:  D E Griswold; J A DiLorenzo; P Calabresi
Journal:  Cell Immunol       Date:  1974-03-30       Impact factor: 4.868

8.  Adjuvant-induced arthritis in rats. I. Temporal relationship of physiological, biochemical, and hematological parameters.

Authors:  D T Walz; M J DiMartino; J H Kuch; W Zuccarello
Journal:  Proc Soc Exp Biol Med       Date:  1971-03

9.  Letter: Levamisole in the treatment of cancer.

Authors:  H W Ward
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

10.  In vitro parameters of cell-mediated immune reactions in healthy individuals following immune-stimulation attempts with levamisole.

Authors:  H Thulin; K Thestrup-Pedersen; J Ellegaard
Journal:  Acta Allergol       Date:  1975-04
View more
  3 in total

1.  Immunopharmacology of gold sodium thiomalate and auranofin (SK&F D-39162): effects on cell-mediated immunity.

Authors:  D T Walz; D E Griswold
Journal:  Inflammation       Date:  1978-06       Impact factor: 4.092

2.  Effect of selected immunoregulatory agents on low-grade contact sensitivity.

Authors:  D E Griswold; D T Walz
Journal:  Inflammation       Date:  1982-03       Impact factor: 4.092

3.  Restoration of methotrexate-suppressed oxazolone-induced contact sensitivity with levamisole.

Authors:  D E Griswold; D T Walz
Journal:  Inflammation       Date:  1978-03       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.